Composition
| Ingredient | Strength |
|---|---|
| Sitagliptin | 100 mg |
| Dapagliflozin | 10 mg |
| Metformin Hydrochloride (extended release) | 500 mg |
Therapeutic use
Triple combination used in the management of type 2 diabetes mellitus, combining a DPP-4 inhibitor, an SGLT2 inhibitor and metformin.
For use under medical supervision only. Dosage, contraindications and precautions are as per the full prescribing information, available to registered medical practitioners on request.
Product details
- Brand name
- OJIDAP-TRIO™
- Therapy range
- Diabetic
- Dosage form
- Tablet
- Pack size
- 10 x 10 tablets
- Number of ingredients
- 3
- Marketed by
- Grori Pharma Pvt Ltd
Frequently asked questions
What is the composition of Ojidap-Trio?
Each unit of Ojidap-Trio contains Sitagliptin 100 mg + Dapagliflozin 10 mg + Metformin Hydrochloride (extended release) 500 mg.
What is Ojidap-Trio used for?
Triple combination used in the management of type 2 diabetes mellitus, combining a DPP-4 inhibitor, an SGLT2 inhibitor and metformin.
Who markets Ojidap-Trio?
Ojidap-Trio is marketed by Grori Pharma Pvt Ltd, Hyderabad, as part of its Diabetic range.
How can I get product information or place an order for Ojidap-Trio?
Doctors, pharmacies and distributors can call +91 95505 94814, +91 96528 45486 or +91 99669 45111, email groripharma@gmail.com, or use the enquiry form on the Grori Pharma contact page.